Elanco Animal Health (ELAN) to Release Earnings on Tuesday

Elanco Animal Health (NYSE:ELAN) is anticipated to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Elanco Animal Health to post earnings of $0.11 per share and revenue of $1.0940 billion for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:00 AM ET.

Elanco Animal Health Price Performance

NYSE ELAN opened at $25.15 on Tuesday. The company has a market cap of $12.50 billion, a price-to-earnings ratio of 419.30, a PEG ratio of 3.76 and a beta of 1.87. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The stock’s fifty day moving average price is $23.53 and its 200 day moving average price is $21.19. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $26.08.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ELAN. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a report on Wednesday, December 10th. Argus upgraded shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Wednesday, November 19th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. Barclays assumed coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, Morgan Stanley raised their target price on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus target price of $25.44.

Insider Activity

In other news, insider Rajeev A. Modi acquired 4,500 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the completion of the transaction, the insider owned 123,082 shares in the company, valued at approximately $2,625,339.06. The trade was a 3.79% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction dated Friday, December 12th. The shares were purchased at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the director owned 131,773 shares in the company, valued at approximately $2,806,764.90. This represents a 8.21% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 43,450 shares of company stock valued at $937,883 in the last quarter. Company insiders own 0.89% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

Large investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. grew its holdings in Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after purchasing an additional 2,080 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Elanco Animal Health by 26.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock valued at $91,000 after buying an additional 1,332 shares in the last quarter. UMB Bank n.a. grew its stake in Elanco Animal Health by 31.9% in the 4th quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock valued at $127,000 after acquiring an additional 1,358 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Elanco Animal Health by 2,532.0% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 6,343 shares of the company’s stock worth $128,000 after acquiring an additional 6,102 shares in the last quarter. Finally, Quadrant Capital Group LLC acquired a new position in Elanco Animal Health during the third quarter worth $145,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.